Names and pronunciation
(ep′ti-nez′ue-mab) Vyepti
PDF page 488
Loading InternPractice…
Drug reference
(ep′ti-nez′ue-mab) Vyepti
PDF page 488
Func. class.: Antimigraine agent
PDF page 488
Chem. class.: Calcitonin gene–related peptide receptor antagonist
PDF page 488
ACTION: A humanized monoclonal antibody, binds to calcitonin gene– related peptide ligand and blocks bind- ing to the receptor
PDF page 488
USES: Prevention of migraine
PDF page 488
CONTRAINDICATIONS: Serious hypersensitivity Precautions: Pregnancy, breastfeeding
PDF page 488
SIDE EFFECTS MISC:Antibody development RESP: Nasopharyngitis CNS: Fatigue GI: Nausea INTEG: Hypersensitivity, angioedema
PDF page 489
INTERACTIONS: None known
PDF page 489
DOSAGE AND ROUTES Migraine prophylaxis • Adult: IV: 100 mg q3mo; may use 300 mg q3mo
PDF page 488
Available forms: solution, preservative free 100 mg/mL (1 mL)
PDF page 489
Administer: Intermittent IV infusion • Contains polysorbate 80 • Dilute in 100 mL NS; infusion bags must be made of polyvinyl chloride, polyethylene, polyolefin; mix by gentle inverting; do not shake, discard unused portion; 100-mg dose: Withdraw 1 mL eptinezumab/100 mL NS (1 mg/mL); 300-mg dose: Withdraw 1 mL eptinezumab from 3 vials/100 mL NS (3 mg/mL) • Run over 30 min using an infusion set with a 0.2 or 0.22 micron in-line or add- on sterile filter; do not give IV push/bolus • Do not admix or infuse other medica- tions in same infusion set • After infusion, flush line with 20 mL NS • Store intact vial at 2°C to 8°C (36°F to 46°F), protect from light, do not freeze; diluted solution may be stored at room temperature, infuse within 8 hr
PDF page 489
Assess: • Migraine: Baseline and periodically, presence of aura, nausea/vomiting • Assess for hypersensitivity, dyspnea; reaction may be delayed, discontinue if these occur
PDF page 489
Evaluate: • Therapeutic response: Prevention of migraine
PDF page 489
CLINICAL CONSIDERATIONS
PDF page 489
Patient and caregiver information: • Reason for product and expected re- sult • Identify if pregnancy is planned or suspected
PDF page 489
PHARMACOKINETICS: Onset 1 day, peak infusion’s end, duration unknown, half-life 27 days
PDF page 489
• Adult: IV: 100 mg q3mo; may use 300 mg q3mo
PDF page 488